Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | CACNA1B | Q00975 | 7/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.46 |
| ▸ | PRCP | P42785 | 1/20 | 0.46 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.46 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.46 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | RPA1 | P27694 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3093919 | 0.84 | KCNJ6 (0.50) | CACNA1BMEN1KMT2AKCNJ6KCNJ5 | |
| SCHEMBL12185963 | 0.82 | KCNJ6 (0.42) | CACNA1BKMT2AKCNJ6KCNJ5KCNJ3 | |
| SCHEMBL12186018 | 0.81 | CACNA1B (0.49) | L3MBTL1CACNA1BMEN1KMT2AMALT1 | |
| SCHEMBL2599117 | 0.81 | PRCP (0.56) | L3MBTL1MEN1KMT2APRCPSMN1; SMN2 | |
| SCHEMBL28330785 | 0.81 | NPC1 (0.56) | CACNA1BKCNJ6KCNJ5KCNJ3MGLL | |
| SCHEMBL14686768 | 0.78 | PRCP (0.57) | L3MBTL1CACNA1BMEN1KMT2AMALT1 | |
| SCHEMBL12185527 | 0.78 | PRCP (0.70) | L3MBTL1CACNA1BMEN1KMT2APRCP | |
| SCHEMBL12185564 | 0.78 | PRCP (0.47) | L3MBTL1CACNA1BMEN1KMT2AMALT1 | |
| SCHEMBL12185551 | 0.78 | PRCP (0.73) | L3MBTL1CACNA1BMEN1KMT2APRCP | |
| SCHEMBL31466203 | 0.78 | CACNA1B (0.44) | CACNA1BPRCPNPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2568812-B1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-10-26 | — | — | EP | disclosed |
| EP-2568812-B1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-10-26 | — | — | EP | disclosed |
| US-9365539-B2 | Prolylcarboxypeptidase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365539-B2 | Prolylcarboxypeptidase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365539-B2 | Prolylcarboxypeptidase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-06-14 | — | — | US | disclosed |
| EP-2568812-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-03-20 | — | — | EP | disclosed |
| US-20130040929-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130040929-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130040929-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-02-14 | — | — | US | disclosed |
| WO-2011143057-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143057-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040929-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | PRCP, PREP, ENPEP | L3MBTL1 2928/4885CACNA1B 4761/4885MEN1 3238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.